Brief: Todos Medical Provides Update On Covid-19 Oral Antiviral 3Cl Protease (Main Protease) Inhibitor Tollovir Clinical Development Program
04/10/2021 12:40
Oct 4 (Reuters) - Todos Medical Ltd TOMDF.PK :
* TODOS MEDICAL PROVIDES UPDATE ON COVID-19 ORAL ANTIVIRAL
3CL
PROTEASE (MAIN PROTEASE) INHIBITOR TOLLOVIR CLINICAL DEVELOPMENT
PROGRAM IN LIGHT OF MOLNUPIRAVIR CLINICAL TRIAL DATA FROM MERCK
Source text for Eikon: ID:nGNE5g63Tv
Further company coverage: TOMDF.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Todos Medical
See all newsBrief: Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Brief: Todos Medical Clia/Cap Lab Provista Submits Emergency Use Authorization Application For Monkeypox Pcr Test To Us FDA
Brief: Todos Medical Provides Corporate Update
Brief: Todos Medical Enters Into $50 Mln Contract To Supply Tollovid, CBD Products To Retail Distributor Company Nerd Hemp
Brief: Todos Medical Establishes Botanical Supplement Manufacturing Capabilities